Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer - Seite 2
About Veru Inc.
Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer. The Veru prostate cancer pipeline includes VERU-111,
VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-111 is
being evaluated in an open label Phase 1b/2 clinical study in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer. The Phase 1b clinical study completed
enrollment of 39 men and is ongoing. The Phase 2 clinical study will enroll 40 men who have metastatic castration resistant prostate cancer and who have also become resistant to at least one novel
androgen receptor targeting agent, such as abiraterone or enzalutamide, but prior to IV chemotherapy. VERU-111 is also being evaluated in a Phase 2 clinical trial to assess the efficacy of VERU-111
in combating COVID-19. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced
prostate cancer. VERU-100 is a long-acting gonadotropin-releasing hormone (GnRH) antagonist administered as a small volume, subcutaneous 3-month depot injection without a loading dose. VERU-100
immediately suppresses testosterone with no testosterone surge upon initial or repeated administration — a problem which occurs with currently approved luteinizing hormone-releasing hormone (LHRH)
agonists used for ADT. There are no GnRH antagonists commercially approved beyond a one-month injection. An IND is expected to be submitted for the Phase 2 study to evaluate VERU-100 dosing in the
fourth quarter of calendar year 2020 and a Phase 2 clinical trial is anticipated to commence Q1 2021. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat
hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. Following an End of Phase 2 meeting with the FDA, the Company plans to advance Zuclomiphene Citrate to a Phase
3 clinical trial in men with advanced prostate cancer who experience moderate to severe hot flashes.